Modern rheumatology · 2026
Retention of baricitinib-treated patients with rheumatoid arthritis in Japan: Interim results from a prospective observational cohort study.
СтатьяНаблюдательное исследованиеМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kaneko Yuko, Wang Chaochen, Tsujimoto Naoto, Tanaka Masaru, Ikeda Kei
Аннотация
OBJECTIVES: To assess the retention rate, changes in disease activity and patient-reported outcomes (PROs), and predictors of treatment discontinuation among baricitinib-treated patients with rheumatoid arthritis (RA) in routine clinical practice in Japan.
METHODS: This ongoing, multi-centre, prospective, observational study (starting February 2021) included ≥20-year-old baricitinib-treated patients with RA. Baricitinib's retention rate and effectiveness were evaluated until 12 months. The association between patient characteristics and retention was evaluated using Random Forest analysis.
RESULTS: This interim analysis included 353 patients (mean [standard deviation; SD] age 63.4 [13.6] years; 70.0% female). The 12-month retention rate was 70.2% (95% confidence interval [CI] 65.1, 74.6). The 12-month remission rates were 35.3%, 41.1%, and 79.6% per Clinical Disease Activity Index, Simplified Disease Activity Index, and Disease Activity Score with 28 joints-C-reactive protein. The mean (SD) changes in PROs from baseline scores were: physician global assessment of disease activity (-33.8 [27.8]), patient global assessment of disease activity (-18.3 [29.4]), Health Assessment Questionnaire-Disability Index (-0.33 [0.53]), and pain (-19.4 [27.0]). Ten variables influenced the model's prediction of treatment discontinuation.
CONCLUSIONS: Evidence from this interim analysis suggested the favourable effectiveness and drug survival of baricitinib in real-world Japanese patients with RA.
METHODS: This ongoing, multi-centre, prospective, observational study (starting February 2021) included ≥20-year-old baricitinib-treated patients with RA. Baricitinib's retention rate and effectiveness were evaluated until 12 months. The association between patient characteristics and retention was evaluated using Random Forest analysis.
RESULTS: This interim analysis included 353 patients (mean [standard deviation; SD] age 63.4 [13.6] years; 70.0% female). The 12-month retention rate was 70.2% (95% confidence interval [CI] 65.1, 74.6). The 12-month remission rates were 35.3%, 41.1%, and 79.6% per Clinical Disease Activity Index, Simplified Disease Activity Index, and Disease Activity Score with 28 joints-C-reactive protein. The mean (SD) changes in PROs from baseline scores were: physician global assessment of disease activity (-33.8 [27.8]), patient global assessment of disease activity (-18.3 [29.4]), Health Assessment Questionnaire-Disability Index (-0.33 [0.53]), and pain (-19.4 [27.0]). Ten variables influenced the model's prediction of treatment discontinuation.
CONCLUSIONS: Evidence from this interim analysis suggested the favourable effectiveness and drug survival of baricitinib in real-world Japanese patients with RA.